Monitor ASN Kidney Week presentations for any real-world efficacy signals or safety updates that could influence physician adoption of XPHOZAH. No immediate trading catalyst.
Price Chart
Executive Summary
Ardelyx announced three abstracts will be presented at ASN Kidney Week 2026, highlighting real-world evidence for tenapanor (XPHOZAH) in hyperphosphatemia, patient perspectives, and morbidity/mortality risks. The company will also host an exhibitor spotlight session on XPHOZAH. This is a routine scientific conference update with no new clinical data or regulatory catalysts — neutral for the stock.
Key Facts
- Three abstracts accepted for poster presentation at ASN Kidney Week 2026 (Oct 21-25, Denver).
- Presentations cover real-world effectiveness of tenapanor, patient perspectives on hyperphosphatemia management, and morbidity/mortality risks of cumulative hyperphosphatemia.
- Ardelyx will host an Exhibitor Spotlight session on XPHOZAH (tenapanor) on Oct 23, 2026.
- XPHOZAH is a first-in-class phosphate absorption inhibitor approved as add-on therapy for dialysis patients with inadequate response to phosphate binders.
- No new clinical data, regulatory decisions, or financial guidance disclosed.
Financial Impact
No financial impact — routine conference presentation without new data or guidance.
Risk Factors
- Real-world data may not show significant differentiation vs. phosphate binders.
- Diarrhea side effect (43-53% incidence) could limit adoption.
- No new revenue or guidance updates — stock likely to trade on fundamentals and upcoming quarterly results.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374508 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | Press Release | $3.39 | awaiting T+20 | — | $3.00 (−11.50%) |
Aug 25, 2026 9w ago | Insider Cluster | $3.83 $3.45 | ▼ −9.92% | ▼ −10.15% | $3.00 (−21.67%) |
Aug 25, 2026 9w ago | Insider Cluster | $3.83 $3.45 | ▼ −9.92% | ▼ −10.15% | $3.00 (−21.67%) |
Aug 21, 2026 9w ago | 144 | $3.74 $3.62 | ▼ −3.21% | ▼ −4.52% | $3.00 (−19.79%) |
Aug 21, 2026 9w ago | 144 | $3.74 $3.62 | ▼ −3.21% | ▼ −4.52% | $3.00 (−19.79%) |
Aug 17, 2026 10w ago | 8-K | $3.92 $3.40 | ▼ −13.27% | ▼ −12.28% | $3.00 (−23.47%) |
Aug 15, 2026 10w ago | Institutional Cluster | $4.06 $3.52 | ▼ −13.30% | ▼ −11.77% | $3.00 (−26.11%) |
Jul 2, 2026 16w ago | 8-K | $5.27 $5.04 | ▼ −4.36% | ▼ −3.95% | $3.00 (−43.07%) |
Jun 17, 2026 18w ago | 8-K | $6.05 $5.13 | ▼ −15.29% | ▼ −15.82% | $3.00 (−50.41%) |
Jun 15, 2026 19w ago | 144 | $5.67 $5.16 | ▼ −8.99% | ▼ −9.19% | $3.00 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers